<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34502310</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1422-0067</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>22</Volume>
            <Issue>17</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Aug</Month>
              <Day>30</Day>
            </PubDate>
          </JournalIssue>
          <Title>International journal of molecular sciences</Title>
          <ISOAbbreviation>Int J Mol Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The Role of ER Stress-Related Phenomena in the Biology of Malignant Peripheral Nerve Sheath Tumors.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">9405</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms22179405</ELocationID>
        <Abstract>
          <AbstractText>Malignant peripheral nerve sheath tumors (MPNST) are rare but one of the most aggressive types of cancer. Currently, there are no effective chemotherapy strategies for these malignancies. The inactivation of the neurofibromatosis type I (NF1) gene, followed by loss of TP53, is an early stage in MPNST carcinogenesis. NF1 is a negative regulator of the Ras proteins family, which are key factors in regulating cell growth, homeostasis and survival. Cell cycle dysregulation induces a stress phenotype, such as proteotoxic stress, metabolic stress, and oxidative stress, which should result in cell death. However, in the case of neoplastic cells, we observe not only the avoidance of apoptosis, but also the impact of stress factors on the treatment effectiveness. This review focuses on the pathomechanisms underlying MPNST cells physiology, and discusses the possible ways to develop a successful treatment based on the molecular background of the disease.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Walczak</LastName>
            <ForeName>Anna</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Chemistry and Biochemistry, Medical University of Lodz, 90-647 Lodz, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Radek</LastName>
            <ForeName>Maciej</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0003-3544-1482</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery and Peripheral Nerve Surgery, Medical University of Lodz, 90-647 Lodz, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Majsterek</LastName>
            <ForeName>Ireneusz</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Chemistry and Biochemistry, Medical University of Lodz, 90-647 Lodz, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>08</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Int J Mol Sci</MedlineTA>
        <NlmUniqueID>101092791</NlmUniqueID>
        <ISSNLinking>1422-0067</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059865" MajorTopicYN="Y">Endoplasmic Reticulum Stress</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018319" MajorTopicYN="N">Neurofibrosarcoma</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ER-stress</Keyword>
        <Keyword MajorTopicYN="N">MPNST</Keyword>
        <Keyword MajorTopicYN="N">UPR</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>10</Day>
          <Hour>1</Hour>
          <Minute>7</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34502310</ArticleId>
        <ArticleId IdType="pmc">PMC8430526</ArticleId>
        <ArticleId IdType="doi">10.3390/ijms22179405</ArticleId>
        <ArticleId IdType="pii">ijms22179405</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Hirbe A.C., Gutmann D.H. The management of neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors: Challenges, progress, and future prospects. Expert Opin. Orphan Drugs. 2017;5:623–631. doi: 10.1080/21678707.2017.1348294.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/21678707.2017.1348294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bottillo I., Ahlquist T., Brekke H., Danielsen S.A., van den Berg E., Mertens F., Lothe R.A., Dallapiccola B. Germline and somatic NF1 mutations in sporadic and NF1-associated malignant peripheral nerve sheath tumours. J. Pathol. 2009;217:693–701. doi: 10.1002/path.2494.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/path.2494</ArticleId>
            <ArticleId IdType="pubmed">19142971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farid M., Demicco E.G., Garcia R., Ahn L., Merola P.R., Cioffi A., Maki R.G. Malignant peripheral nerve sheath tumors. Oncologist. 2014;19:193–201. doi: 10.1634/theoncologist.2013-0328.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1634/theoncologist.2013-0328</ArticleId>
            <ArticleId IdType="pmc">PMC3926794</ArticleId>
            <ArticleId IdType="pubmed">24470531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pala-Sadza A., Zajączkiewicz H., Banaś-Samson R., Glinianowicz I., Ożóg J., Gnacik-Stawarczyk E., Dubrawska M., Rauch B. Rzadki przypadek złośliwego nerwiaka osłonkowego jamy nosa. Pol. Przegląd Otorynolaryngologiczny. 2014;3:210–213. doi: 10.1016/j.ppotor.2014.08.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ppotor.2014.08.004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ralli M., Singh S., Hasija S., Verma R. Intrathoracic Malignant Peripheral Nerve Sheath Tumor: Histopathological and Immunohistochemical Features. Iran. J. Pathol. 2015;10:74–78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4539789</ArticleId>
            <ArticleId IdType="pubmed">26516330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watson K.L., Al Sannaa G.A., Kivlin C.M., Ingram D.R., Landers S.M., Roland C.L., Cormier J.N., Hunt K.K., Feig B.W., Ashleigh Guadagnolo B., et al.  Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors. J. Neurosurg. 2017;126:319–329. doi: 10.3171/2015.12.JNS152443.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3171/2015.12.JNS152443</ArticleId>
            <ArticleId IdType="pmc">PMC5045773</ArticleId>
            <ArticleId IdType="pubmed">27035165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cai Z., Tang X., Liang H., Yang R., Yan T., Guo W. Prognosis and risk factors for malignant peripheral nerve sheath tumor: A systematic review and meta-analysis. World J. Surg Oncol. 2020;18:257. doi: 10.1186/s12957-020-02036-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12957-020-02036-x</ArticleId>
            <ArticleId IdType="pmc">PMC7528472</ArticleId>
            <ArticleId IdType="pubmed">32998743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maane L.A., Bouzidi A.A.L., Damou M., Ismaili N. Primary intrapulmonary malignant peripheral nerve sheath tumor: A rare case. Cancer Treat. Res. Commun. 2020;25:100243. doi: 10.1016/j.ctarc.2020.100243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ctarc.2020.100243</ArticleId>
            <ArticleId IdType="pubmed">33260029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morimoto A., Asai J., Wakabayashi Y., Tashima S., Wada M., Iida S., Komori S., Hanada K., Takenaka H., Katoh N. Lymph node metastasis of a malignant peripheral nerve sheath tumor without distant metastasis. Indian J. Dermatol. 2014;59:635.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4248547</ArticleId>
            <ArticleId IdType="pubmed">25484439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meng Z.H., Yang Y.S., Cheng K.L., Chen G.Q., Wang L.P., Li W. A huge malignant peripheral nerve sheath tumor with hepatic metastasis arising from retroperitoneal ganglioneuroma. Oncol. Lett. 2013;5:123–126. doi: 10.3892/ol.2012.961.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2012.961</ArticleId>
            <ArticleId IdType="pmc">PMC3525478</ArticleId>
            <ArticleId IdType="pubmed">23255906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malone C.F., Emerson C., Ingraham R., Barbosa W., Guerra S., Yoon H., Liu L.L., Michor F., Haigis M., Macleod K.F., et al.  mTOR and HDAC inhibitors converge on the TXNIP/thioredoxin pathway to cause catastrophic oxidative stress and regression of RAS-driven tumors. Cancer Discov. 2017;7:1450–1463. doi: 10.1158/2159-8290.CD-17-0177.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-17-0177</ArticleId>
            <ArticleId IdType="pmc">PMC5718976</ArticleId>
            <ArticleId IdType="pubmed">28963352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fukushima S., Endo M., Matsumoto Y., Fukushi J.I., Matsunobu T., Kawaguchi K.I., Setsu N., IIda K., Yokoyama N., Nakagawa M., et al.  Hypoxia-inducible factor 1 alpha is a poor prognostic factor and potential therapeutic target in malignant peripheral nerve sheath tumor. PLoS ONE. 2017;12:e0178064.  doi: 10.1371/journal.pone.0178064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0178064</ArticleId>
            <ArticleId IdType="pmc">PMC5448771</ArticleId>
            <ArticleId IdType="pubmed">28558056</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castorina A., Giunta S., Scuderi S., D’Agata V. Involvement of PACAP/ADNP signaling in the resistance to cell death in malignant peripheral nerve sheath tumor (MPNST) cells. J. Mol. Neurosci. 2012;48:674–683. doi: 10.1007/s12031-012-9755-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12031-012-9755-z</ArticleId>
            <ArticleId IdType="pubmed">22454142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corazzari M., Gagliardi M., Fimia G.M., Piacentini M. Endoplasmic reticulum stress, unfolded protein response, and cancer cell fate. Front. Oncol. 2017;7:78. doi: 10.3389/fonc.2017.00078.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2017.00078</ArticleId>
            <ArticleId IdType="pmc">PMC5405076</ArticleId>
            <ArticleId IdType="pubmed">28491820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taipale M., Jarosz D.F., Lindquist S. HSP90 at the hub of protein homeostasis: Emerging mechanistic insights. Nat. Reviews. Mol. Cell Biol. 2010;11:515–528. doi: 10.1038/nrm2918.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm2918</ArticleId>
            <ArticleId IdType="pubmed">20531426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chipurupalli S., Kannan E., Tergaonkar V., D’Andrea R., Robinson N. Hypoxia induced ER stress response as an adaptive mechanism in cancer. Int. J. Mol. Sci. 2019;20:749.  doi: 10.3390/ijms20030749.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms20030749</ArticleId>
            <ArticleId IdType="pmc">PMC6387291</ArticleId>
            <ArticleId IdType="pubmed">30754624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blazanin N., Son J., Craig-Lucas A.B., John C.L., Breech K.J., Podolsky M.A., Glick A.B. ER stress and distinct outputs of the IRE1α RNase control proliferation and senescence in response to oncogenic Ras. Proc. Natl. Acad. Sci. USA. 2017;114:9900–9905. doi: 10.1073/pnas.1701757114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1701757114</ArticleId>
            <ArticleId IdType="pmc">PMC5603998</ArticleId>
            <ArticleId IdType="pubmed">28847931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oslowski C.M., Urano F. Measuring ER stress and the unfolded protein response using mammalian tissue culture system. Methods Enzymol. 2011;490:71–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3701721</ArticleId>
            <ArticleId IdType="pubmed">21266244</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang Y.C., Williams B.R., Siegel J.J., Amon A. Identification of aneuploidy-selective antiproliferation compounds. Cell. 2011;144:499–512. doi: 10.1016/j.cell.2011.01.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2011.01.017</ArticleId>
            <ArticleId IdType="pmc">PMC3532042</ArticleId>
            <ArticleId IdType="pubmed">21315436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Limonta P., Moretti R.M., Marzagalli M., Fontana F., Raimondi M., Montagnani Marelli M. Role of endoplasmic reticulum stress in the anticancer activity of natural compounds. Int. J. Mol. Sci. 2019;20:961.  doi: 10.3390/ijms20040961.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms20040961</ArticleId>
            <ArticleId IdType="pmc">PMC6412802</ArticleId>
            <ArticleId IdType="pubmed">30813301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yadav R.K., Chae S.-W., Kim H.-R., Chae H.J. Endoplasmic reticulum stress and cancer. J. Cancer Prev. 2014;19:75–88. doi: 10.15430/JCP.2014.19.2.75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15430/JCP.2014.19.2.75</ArticleId>
            <ArticleId IdType="pmc">PMC4204165</ArticleId>
            <ArticleId IdType="pubmed">25337575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang M., Wang Y., Jones S., Sausen M., McMahon K., Sharma R., Wang Q., Belzberg A.J., Chaichana K., Gallia G.L., et al.  Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. Nat. Genet. 2014;46:1170–1172. doi: 10.1038/ng.3116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.3116</ArticleId>
            <ArticleId IdType="pmc">PMC4383254</ArticleId>
            <ArticleId IdType="pubmed">25305755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beert E., Brems H., Daniëls B., De Wever I., Van Calenbergh F., Schoenaers J., Debiec-Rychter M., Gevaert O., De Raedt T., Van Den Bruel A., et al.  Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. Genes Chromosomes Cancer. 2011;50:1021–1032. doi: 10.1002/gcc.20921.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/gcc.20921</ArticleId>
            <ArticleId IdType="pubmed">21987445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirbe A.C., Dahiya S., Miller C.A., Li T., Fulton R.S., Zhang X., McDonald S., DeSchryver K., Duncavage E.J., Walrath J., et al.  Whole exome sequencing reveals the order of genetic changes during malignant transformation and metastasis in a single patient with NF1-plexiform neurofibroma. Clin. Cancer Res. 2015;21:4201–4211. doi: 10.1158/1078-0432.CCR-14-3049.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-14-3049</ArticleId>
            <ArticleId IdType="pmc">PMC4573781</ArticleId>
            <ArticleId IdType="pubmed">25925892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carroll S.L. The challenge of cancer genomics in rare nervous system neoplasms: Malignant peripheral nerve sheath tumors as a paradigm for cross-species comparative oncogenomics. Am. J. Pathol. 2016;186:464–477. doi: 10.1016/j.ajpath.2015.10.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajpath.2015.10.023</ArticleId>
            <ArticleId IdType="pmc">PMC4816695</ArticleId>
            <ArticleId IdType="pubmed">26740486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J., Liu W., Williams J.P., Ratner N. EGFR-Stat3 signalling in nerve glial cells modifies neurofibroma initiation. Oncogene. 2017;36:1669–1677. doi: 10.1038/onc.2016.386.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2016.386</ArticleId>
            <ArticleId IdType="pmc">PMC5502541</ArticleId>
            <ArticleId IdType="pubmed">27748759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li H., Velasco-Miguel S., Vass W.C., Parada L.F., DeClue J.E. Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the Nf1:p53 mouse tumor model. Cancer Res. 2002;62:4507–4513.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12154062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wiles E.T., Selker E.U. H3K27 methylation: A promiscuous repressive chromatin mark. Curr. Opin. Genet. Dev. 2017;43:31–37. doi: 10.1016/j.gde.2016.11.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gde.2016.11.001</ArticleId>
            <ArticleId IdType="pmc">PMC5447479</ArticleId>
            <ArticleId IdType="pubmed">27940208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Raedt T., Beert E., Pasmant E., Luscan A., Brems H., Ortonne N., Helin K., Hornick J.L., Mautner V., Kehrer-Sawatzki H., et al.  PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature. 2014;514:247–251. doi: 10.1038/nature13561.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature13561</ArticleId>
            <ArticleId IdType="pubmed">25119042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee W., Teckie S., Wiesner T., Ran L., Granada C., Lin M., Zhu S., Cao Z., Liang Y., Sboner A., et al.  PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat. Genet. 2014;46:1227–1232. doi: 10.1038/ng.3095.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.3095</ArticleId>
            <ArticleId IdType="pmc">PMC4249650</ArticleId>
            <ArticleId IdType="pubmed">25240281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie B., Fan X., Lei Y., Chen R., Wang J., Fu C., Yi S., Luo J., Zhang S., Yang Q., et al.  A novel de novo microdeletion at 17q11.2 adjacent to NF1 gene associated with developmental delay, short stature, microcephaly and dysmorphic features. Mol. Cytogenet. 2016;9:41. doi: 10.1186/s13039-016-0251-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13039-016-0251-y</ArticleId>
            <ArticleId IdType="pmc">PMC4886423</ArticleId>
            <ArticleId IdType="pubmed">27247625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cleven A.H., Sannaa G.A., Briaire-de Bruijn I., Ingram D.R., van de Rijn M., Rubin B.P., de Vries M.W., Watson K.L., Torres K.E., Wang W.L., et al.  Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. Mod. Pathol. 2016;29:582–590. doi: 10.1038/modpathol.2016.45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/modpathol.2016.45</ArticleId>
            <ArticleId IdType="pmc">PMC4948583</ArticleId>
            <ArticleId IdType="pubmed">26990975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meany H., Dombi E., Reynolds J., Whatley M., Kurwa A., Tsokos M., Salzer W., Gillespie A., Baldwin A., Derdak J., et al.  18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with Neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST) Pediatric Blood Cancer. 2013;60:59–64. doi: 10.1002/pbc.24212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pbc.24212</ArticleId>
            <ArticleId IdType="pmc">PMC6626667</ArticleId>
            <ArticleId IdType="pubmed">22645095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vasudevan A., Schukken K.M., Sausville E.L., Girish V., Adebambo O.A., Sheltzer J.M. Aneuploidy as a promoter and suppressor of malignant growth. Nat. Rev. Cancer. 2021;21:89–103. doi: 10.1038/s41568-020-00321-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41568-020-00321-1</ArticleId>
            <ArticleId IdType="pubmed">33432169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oromendia A.B., Amon A. Aneuploidy: Implications for protein homeostasis and disease. Dis. Models Mech. 2014;7:15–20. doi: 10.1242/dmm.013391.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/dmm.013391</ArticleId>
            <ArticleId IdType="pmc">PMC3882044</ArticleId>
            <ArticleId IdType="pubmed">24396150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheltzer J.M., Torres E.M., Dunham M.J., Amon A. Transcriptional consequences of aneuploidy. Proc. Natl. Acad. Sci. USA. 2012;109:12644–12649. doi: 10.1073/pnas.1209227109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1209227109</ArticleId>
            <ArticleId IdType="pmc">PMC3411958</ArticleId>
            <ArticleId IdType="pubmed">22802626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oromendia A.B., Dodgson S.E., Amon A. Aneuploidy causes proteotoxic stress in yeast. Genes Dev. 2012;26:2696–2708. doi: 10.1101/gad.207407.112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.207407.112</ArticleId>
            <ArticleId IdType="pmc">PMC3533075</ArticleId>
            <ArticleId IdType="pubmed">23222101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohashi A., Ohori M., Iwai K., Nakayama Y., Nambu T., Morishita D., Kawamoto T., Miyamoto M., Hirayama T., Okaniwa M., et al.  Aneuploidy generates proteotoxic stress and DNA damage concurrently with p53-mediated post-mitotic apoptosis in SAC-impaired cells. Nat. Commun. 2015;6:7668. doi: 10.1038/ncomms8668.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms8668</ArticleId>
            <ArticleId IdType="pmc">PMC4506520</ArticleId>
            <ArticleId IdType="pubmed">26144554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bridge R.S., Jr., Bridge J.A., Neff J.R., Naumann S., Althof P., Bruch L.A. Recurrent chromosomal imbalances and structurally abnormal breakpoints within complex karyotypes of malignant peripheral nerve sheath tumour and malignant triton tumour: A cytogenetic and molecular cytogenetic study. J. Clin. Pathol. 2004;57:1172–1178. doi: 10.1136/jcp.2004.019026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jcp.2004.019026</ArticleId>
            <ArticleId IdType="pmc">PMC1770473</ArticleId>
            <ArticleId IdType="pubmed">15509679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Torres E.M., Dephoure N., Panneerselvam A., Tucker C.M., Whittaker C.A., Gygi S.P., Dunham M.J., Amon A. Identification of aneuploidy-tolerating mutations. Cell. 2010;143:71–83. doi: 10.1016/j.cell.2010.08.038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2010.08.038</ArticleId>
            <ArticleId IdType="pmc">PMC2993244</ArticleId>
            <ArticleId IdType="pubmed">20850176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dai C., Santagata S., Tang Z., Shi J., Cao J., Kwon H., Bronson R.T., Whitesell L., Lindquist S. Loss of tumor suppressor NF1 activates HSF1 to promote carcinogenesis. J. Clin. Investig. 2012;122:3742–3754. doi: 10.1172/JCI62727.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI62727</ArticleId>
            <ArticleId IdType="pmc">PMC3461912</ArticleId>
            <ArticleId IdType="pubmed">22945628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pobre K.F.R., Poet G.J. The endoplasmic reticulum (ER) chaperone BiP is a master regulator of ER functions: Getting by with a little help from ERdj friends. J. Biol. Chem. 2019;294:2098–2108. doi: 10.1074/jbc.REV118.002804.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.REV118.002804</ArticleId>
            <ArticleId IdType="pmc">PMC6369273</ArticleId>
            <ArticleId IdType="pubmed">30563838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Raedt T., Walton Z., Yecies J.L., Li D., Chen Y., Malone C.F., Maertens O., Jeong S.M., Bronson R.T., Lebleu V., et al.  Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell. 2011;20:400–413. doi: 10.1016/j.ccr.2011.08.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2011.08.014</ArticleId>
            <ArticleId IdType="pmc">PMC3233475</ArticleId>
            <ArticleId IdType="pubmed">21907929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang M., Kaufman R.J. Protein misfolding in the endoplasmic reticulum as a conduit to human disease. Nature. 2016;529:326–335. doi: 10.1038/nature17041.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature17041</ArticleId>
            <ArticleId IdType="pubmed">26791723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang S., Xing Y., Liu Y. Emerging roles for the ER stress sensor IRE1α in metabolic regulation and disease. J. Biol. Chem. 2019;294:18726–18741. doi: 10.1074/jbc.REV119.007036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.REV119.007036</ArticleId>
            <ArticleId IdType="pmc">PMC6901316</ArticleId>
            <ArticleId IdType="pubmed">31666338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carrara M., Prischi F., Ali M.M.U. UPR signal activation by luminal sensor domains. Int. J. Mol. Sci. 2013;14:6454–6466. doi: 10.3390/ijms14036454.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms14036454</ArticleId>
            <ArticleId IdType="pmc">PMC3634511</ArticleId>
            <ArticleId IdType="pubmed">23519110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoo J.Y., Hurwitz B.S., Bolyard C., Yu J.G., Zhang J., Selvendiran K., Rath K.S., He S., Bailey Z., Eaves D., et al.  Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects. Clin. Cancer Res. 2014;20:3787–3798. doi: 10.1158/1078-0432.CCR-14-0553.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-14-0553</ArticleId>
            <ArticleId IdType="pmc">PMC4132885</ArticleId>
            <ArticleId IdType="pubmed">24815720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Endo M., Yamamoto H., Setsu N., Kohashi K., Takahashi Y., Ishii T., Iida K., Matsumoto Y., Hakozaki M., Aoki M., et al.  Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors. Clin. Cancer Res. 2013;19:450–461. doi: 10.1158/1078-0432.CCR-12-1067.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-12-1067</ArticleId>
            <ArticleId IdType="pubmed">23209032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rad E., Dodd K., Thomas L., Upadhyaya M., Tee A. STAT3 and HIF1α signaling drives oncogenic cellular phenotypes in malignant peripheral nerve sheath tumors. Mol. Cancer Res. 2015;13:1149–1160. doi: 10.1158/1541-7786.MCR-14-0182.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1541-7786.MCR-14-0182</ArticleId>
            <ArticleId IdType="pubmed">25833823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oslowski C.M., Hara T., O’Sullivan-Murphy B., Kanekura K., Lu S., Hara M., Ishigaki S., Zhu L.J., Hayashi E., Hui S.T., et al.  Thioredoxin-interacting protein mediates ER stress-induced β cell death through initiation of the inflammasome. Cell Metab. 2012;16:265–273. doi: 10.1016/j.cmet.2012.07.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmet.2012.07.005</ArticleId>
            <ArticleId IdType="pmc">PMC3418541</ArticleId>
            <ArticleId IdType="pubmed">22883234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al Tameemi W., Dale T.P., Al-Jumaily R.M.K., Forsyth N.R. Hypoxia-modified cancer cell metabolism. Front. Cell Dev. Biol. 2019;7:4. doi: 10.3389/fcell.2019.00004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fcell.2019.00004</ArticleId>
            <ArticleId IdType="pmc">PMC6362613</ArticleId>
            <ArticleId IdType="pubmed">30761299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muz B., de la Puente P., Azab F., Azab A.K. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia. 2015;3:83–92. doi: 10.2147/HP.S93413.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/HP.S93413</ArticleId>
            <ArticleId IdType="pmc">PMC5045092</ArticleId>
            <ArticleId IdType="pubmed">27774485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corrado C., Fontana S. Hypoxia and HIF signaling: One axis with divergent effects. Int. J. Mol. Sci. 2020;21:5611.  doi: 10.3390/ijms21165611.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms21165611</ArticleId>
            <ArticleId IdType="pmc">PMC7460602</ArticleId>
            <ArticleId IdType="pubmed">32764403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sendoel A., Hengartner M.O. Apoptotic cell death under hypoxia. Physiology. 2014;29:168–176. doi: 10.1152/physiol.00016.2013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/physiol.00016.2013</ArticleId>
            <ArticleId IdType="pubmed">24789981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wasa J., Nishida Y., Suzuki Y., Tsukushi S., Shido Y., Hosono K., Shimoyama Y., Nakamura S., Ishiguro N. Differential expression of angiogenic factors in peripheral nerve sheath tumors. Clin. Exp. Metastasis. 2008;25:819–825. doi: 10.1007/s10585-008-9197-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10585-008-9197-8</ArticleId>
            <ArticleId IdType="pubmed">18679811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masoud G.N., Li W. HIF-1α pathway: Role, regulation and intervention for cancer therapy. Acta Pharm. Sin. B. 2015;5:378–389. doi: 10.1016/j.apsb.2015.05.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.apsb.2015.05.007</ArticleId>
            <ArticleId IdType="pmc">PMC4629436</ArticleId>
            <ArticleId IdType="pubmed">26579469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gampala S., Shah F., Zhang C., Rhodes S.D., Babb O., Grimard M., Wireman R.S., Rad E., Calver B., Bai R.-Y., et al.  Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. Br. J. Cancer. 2021;124:1566–1580. doi: 10.1038/s41416-021-01270-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41416-021-01270-8</ArticleId>
            <ArticleId IdType="pmc">PMC8076291</ArticleId>
            <ArticleId IdType="pubmed">33658640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krawczyk M.A., Kunc M. High expression of solute carrier family 2 member 1 (SLC2A1) in cancer cells is an independent unfavorable prognostic factor in pediatric malignant peripheral nerve sheath tumor. Diagnostics. 2021;11:598.  doi: 10.3390/diagnostics11040598.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/diagnostics11040598</ArticleId>
            <ArticleId IdType="pmc">PMC8065586</ArticleId>
            <ArticleId IdType="pubmed">33810575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liou G.Y., Storz P. Reactive oxygen species in cancer. Free. Radic. Res. 2010;44:479–496. doi: 10.3109/10715761003667554.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/10715761003667554</ArticleId>
            <ArticleId IdType="pmc">PMC3880197</ArticleId>
            <ArticleId IdType="pubmed">20370557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>NavaneethaKrishnan S., Rosales J.L., Lee K.Y. ROS-mediated cancer cell killing through dietary phytochemicals. Oxidative Med. Cell. Longev. 2019;2019:9051542. doi: 10.1155/2019/9051542.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2019/9051542</ArticleId>
            <ArticleId IdType="pmc">PMC6536988</ArticleId>
            <ArticleId IdType="pubmed">31217841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brewer T.F., Garcia F.J., Onak C.S., Carroll K.S., Chang C.J. Chemical approaches to discovery and study of sources and targets of hydrogen peroxide redox signaling through NADPH oxidase proteins. Annu. Rev. Biochem. 2015;84:765–790. doi: 10.1146/annurev-biochem-060614-034018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-biochem-060614-034018</ArticleId>
            <ArticleId IdType="pmc">PMC6063359</ArticleId>
            <ArticleId IdType="pubmed">26034893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maertens O., Johnson B., Hollstein P., Frederick D.T., Cooper Z.A., Messiaen L., Bronson R.T., McMahon M., Granter S., Flaherty K., et al.  Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov. 2013;3:338–349. doi: 10.1158/2159-8290.CD-12-0313.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-12-0313</ArticleId>
            <ArticleId IdType="pmc">PMC3595355</ArticleId>
            <ArticleId IdType="pubmed">23171796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gorrini C., Harris I.S., Mak T.W. Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Discov. 2013;12:931–947. doi: 10.1038/nrd4002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrd4002</ArticleId>
            <ArticleId IdType="pubmed">24287781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>TRPA1-mediated Ca2+ influx protects tumor cells from oxidative stress. Cancer Discov. 2018;8:790.</Citation>
        </Reference>
        <Reference>
          <Citation>Miller S.J., Jessen W.J., Mehta T., Hardiman A., Sites E., Kaiser S., Jegga A.G., Li H., Upadhyaya M., Giovannini M. Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. EMBO Mol. Med. 2009;1:236–248. doi: 10.1002/emmm.200900027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/emmm.200900027</ArticleId>
            <ArticleId IdType="pmc">PMC3378132</ArticleId>
            <ArticleId IdType="pubmed">20049725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takahashi N., Chen H.-Y., Harris I.S., Stover D.G., Selfors L.M., Bronson R.T., Deraedt T., Cichowski K., Welm A.L., Mori Y., et al.  Cancer cells Co-opt the neuronal redox-sensing channel TRPA1 to promote oxidative-stress tolerance. Cancer Cell. 2018;33:985–1003.e7. doi: 10.1016/j.ccell.2018.05.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2018.05.001</ArticleId>
            <ArticleId IdType="pmc">PMC6100788</ArticleId>
            <ArticleId IdType="pubmed">29805077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonnans C., Chou J., Werb Z. Remodelling the extracellular matrix in development and disease. Nat. Rev. Mol. Cell Biol. 2014;15:786–801. doi: 10.1038/nrm3904.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm3904</ArticleId>
            <ArticleId IdType="pmc">PMC4316204</ArticleId>
            <ArticleId IdType="pubmed">25415508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jia X., Chen C., Chen L., Yu C., Kondo T. Decorin as a prognostic biomarker in patients with malignant peripheral nerve sheath tumors. Oncol. Lett. 2019;17:3517–3522. doi: 10.3892/ol.2019.9959.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2019.9959</ArticleId>
            <ArticleId IdType="pmc">PMC6396138</ArticleId>
            <ArticleId IdType="pubmed">30867792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee P.R., Cohen J.E., Tendi E.A., Farrer R., De Vries G.H., Becker K.G., Fields R.D. Transcriptional profiling in an MPNST-derived cell line and normal human Schwann cells. Neuron Glia Biol. 2004;1:135–147. doi: 10.1017/S1740925X04000274.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1017/S1740925X04000274</ArticleId>
            <ArticleId IdType="pmc">PMC1325299</ArticleId>
            <ArticleId IdType="pubmed">16429615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mellier G., Pervaiz S. The three Rs along the TRAIL: Resistance, re-sensitization and reactive oxygen species (ROS) Free. Radic. Res. 2012;46:996–1003. doi: 10.3109/10715762.2012.690514.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/10715762.2012.690514</ArticleId>
            <ArticleId IdType="pubmed">22559302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reuss D.E., Mucha J., Hagenlocher C., Ehemann V., Kluwe L., Mautner V., von Deimling A. Sensitivity of malignant peripheral nerve sheath tumor cells to TRAIL is augmented by loss of NF1 through modulation of MYC/MAD and is potentiated by curcumin through induction of ROS. PLoS ONE. 2013;8:e57152.  doi: 10.1371/journal.pone.0057152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0057152</ArticleId>
            <ArticleId IdType="pmc">PMC3578816</ArticleId>
            <ArticleId IdType="pubmed">23437333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee M.J., Hung S.H., Huang M.C., Tsai T., Chen C.T. Doxycycline potentiates antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy in malignant peripheral nerve sheath tumor cells. PLoS ONE. 2017;12:e0178493.  doi: 10.1371/journal.pone.0178493.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0178493</ArticleId>
            <ArticleId IdType="pmc">PMC5448821</ArticleId>
            <ArticleId IdType="pubmed">28558025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liberti M.V., Locasale J.W. The warburg effect: How does it benefit cancer cells? Trends Biochem. Sci. 2016;41:211–218. doi: 10.1016/j.tibs.2015.12.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tibs.2015.12.001</ArticleId>
            <ArticleId IdType="pmc">PMC4783224</ArticleId>
            <ArticleId IdType="pubmed">26778478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bolaños J.P., Almeida A., Moncada S. Glycolysis: A bioenergetic or a survival pathway? Trends Biochem. Sci. 2010;35:145–149. doi: 10.1016/j.tibs.2009.10.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tibs.2009.10.006</ArticleId>
            <ArticleId IdType="pubmed">20006513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumari S., Badana A.K., G M.M., G S., Malla R. Reactive oxygen species: A key constituent in cancer survival. Biomark Insights. 2018;13 doi: 10.1177/1177271918755391.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1177271918755391</ArticleId>
            <ArticleId IdType="pmc">PMC5808965</ArticleId>
            <ArticleId IdType="pubmed">29449774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diaz-Ruiz R., Rigoulet M., Devin A. The warburg and crabtree effects: On the origin of cancer cell energy metabolism and of yeast glucose repression. Biochim. Biophys. Acta. 2011;1807:568–576. doi: 10.1016/j.bbabio.2010.08.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbabio.2010.08.010</ArticleId>
            <ArticleId IdType="pubmed">20804724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Linke C., Wösle M., Harder A. Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model. BMC Cancer. 2020;20:896.  doi: 10.1186/s12885-020-07397-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12885-020-07397-w</ArticleId>
            <ArticleId IdType="pmc">PMC7501688</ArticleId>
            <ArticleId IdType="pubmed">32948135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Finicle B.T., Jayashankar V., Edinger A.L. Nutrient scavenging in cancer. Nat. Rev. Cancer. 2018;18:619–633. doi: 10.1038/s41568-018-0048-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41568-018-0048-x</ArticleId>
            <ArticleId IdType="pubmed">30097614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Macchioni L., Davidescu M., Sciaccaluga M., Marchetti C., Migliorati G., Coaccioli S., Roberti R., Corazzi L., Castigli E. Mitochondrial dysfunction and effect of antiglycolytic bromopyruvic acid in GL15 glioblastoma cells. J. Bioenerg. Biomembr. 2011;43:507. doi: 10.1007/s10863-011-9375-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10863-011-9375-2</ArticleId>
            <ArticleId IdType="pubmed">21833601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee S.B., Kim H.J., Shin J., Kang S.T., Kang S., Yoo Y.D. Bcl-XL prevents serum deprivation-induced oxidative stress mediated by Romo1. Oncol. Rep. 2011;25:1337–1342.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21399876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moncsek A., Gruner M., Meyer H., Lehmann A., Kloetzel P.M., Stohwasser R. Evidence for anti-apoptotic roles of proteasome activator 28γ via inhibiting caspase activity. Apoptosis. 2015;20:1211–1228. doi: 10.1007/s10495-015-1149-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10495-015-1149-6</ArticleId>
            <ArticleId IdType="pubmed">26201457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>San-Millán I., Brooks G.A. Reexamining cancer metabolism: Lactate production for carcinogenesis could be the purpose and explanation of the warburg effect. Carcinogenesis. 2017;38:119–133. doi: 10.1093/carcin/bgw127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/carcin/bgw127</ArticleId>
            <ArticleId IdType="pmc">PMC5862360</ArticleId>
            <ArticleId IdType="pubmed">27993896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le A., Cooper C.R., Gouw A.M., Dinavahi R., Maitra A., Deck L.M., Royer R.E., Vander Jagt D.L., Semenza G.L., Dang C.V. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc. Natl. Acad. Sci. USA. 2010;107:2037–2042. doi: 10.1073/pnas.0914433107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0914433107</ArticleId>
            <ArticleId IdType="pmc">PMC2836706</ArticleId>
            <ArticleId IdType="pubmed">20133848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mishra D., Banerjee D. Lactate Dehydrogenases as metabolic links between tumor and stroma in the tumor microenvironment. Cancers. 2019;11:750.  doi: 10.3390/cancers11060750.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers11060750</ArticleId>
            <ArticleId IdType="pmc">PMC6627402</ArticleId>
            <ArticleId IdType="pubmed">31146503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bergoug M., Doudeau M., Godin F., Mosrin C., Vallée B., Bénédetti H. Neurofibromin structure, functions and regulation. Cells. 2020;9:2365.  doi: 10.3390/cells9112365.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cells9112365</ArticleId>
            <ArticleId IdType="pmc">PMC7692384</ArticleId>
            <ArticleId IdType="pubmed">33121128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tao J., Sun D., Dong L., Zhu H., Hou H. Advancement in research and therapy of NF1 mutant malignant tumors. Cancer Cell Int. 2020;20:492. doi: 10.1186/s12935-020-01570-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12935-020-01570-8</ArticleId>
            <ArticleId IdType="pmc">PMC7547409</ArticleId>
            <ArticleId IdType="pubmed">33061844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johannessen C.M., Reczek E.E., James M.F., Brems H., Legius E., Cichowski K. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc. Natl. Acad. Sci. USA. 2005;102:8573. doi: 10.1073/pnas.0503224102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0503224102</ArticleId>
            <ArticleId IdType="pmc">PMC1142482</ArticleId>
            <ArticleId IdType="pubmed">15937108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johannessen C.M., Johnson B.W., Williams S.M., Chan A.W., Reczek E.E., Lynch R.C., Rioth M.J., McClatchey A., Ryeom S., Cichowski K. TORC1 is essential for NF1-associated malignancies. Curr. Biol. CB. 2008;18:56–62. doi: 10.1016/j.cub.2007.11.066.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cub.2007.11.066</ArticleId>
            <ArticleId IdType="pubmed">18164202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Denoyelle C., Abou-Rjaily G., Bezrookove V., Verhaegen M., Johnson T.M., Fullen D.R., Pointer J.N., Gruber S.B., Su L.D., Nikiforov M.A., et al.  Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat. Cell Biol. 2006;8:1053–1063. doi: 10.1038/ncb1471.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb1471</ArticleId>
            <ArticleId IdType="pubmed">16964246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Whitesell L., Lindquist S.L. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer. 2005;5:761–772. doi: 10.1038/nrc1716.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc1716</ArticleId>
            <ArticleId IdType="pubmed">16175177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marcu M.G., Doyle M., Bertolotti A., Ron D., Hendershot L., Neckers L. Heat shock protein 90 modulates the unfolded protein response by stabilizing IRE1α. Mol. Cell. Biol. 2002;22:8506–8513. doi: 10.1128/MCB.22.24.8506-8513.2002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.22.24.8506-8513.2002</ArticleId>
            <ArticleId IdType="pmc">PMC139892</ArticleId>
            <ArticleId IdType="pubmed">12446770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim A., Lu Y., Okuno S.H., Reinke D., Maertens O., Perentesis J., Basu M., Wolters P.L., De Raedt T., Chawla S., et al.  Targeting refractory sarcomas and malignant peripheral nerve sheath tumors in a Phase I/II study of sirolimus in combination with ganetespib (SARC023) Sarcoma. 2020;2020:5784876. doi: 10.1155/2020/5784876.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2020/5784876</ArticleId>
            <ArticleId IdType="pmc">PMC7013290</ArticleId>
            <ArticleId IdType="pubmed">32089640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karpel-Massler G., Shu C., Chau L., Banu M., Halatsch M.E., Westhoff M.A., Ramirez Y., Ross A.H., Bruce J.N., Canoll P., et al.  Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo. Oncotarget. 2015;6:14507–14521. doi: 10.18632/oncotarget.3993.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.3993</ArticleId>
            <ArticleId IdType="pmc">PMC4546483</ArticleId>
            <ArticleId IdType="pubmed">26008975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murtaza M., Jolly L.A., Gecz J., Wood S.A. La FAM fatale: USP9X in development and disease. Cell. Mol. Life Sci. 2015;72:2075–2089. doi: 10.1007/s00018-015-1851-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00018-015-1851-0</ArticleId>
            <ArticleId IdType="pmc">PMC4427618</ArticleId>
            <ArticleId IdType="pubmed">25672900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang B., Zhang S., Wang Z., Yang C., Ouyang W., Zhou F., Zhou Y., Xie C. Deubiquitinase USP9X deubiquitinates β-catenin and promotes high grade glioma cell growth. Oncotarget. 2016;7:79515–79525. doi: 10.18632/oncotarget.12819.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.12819</ArticleId>
            <ArticleId IdType="pmc">PMC5346732</ArticleId>
            <ArticleId IdType="pubmed">27783990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Engel K., Rudelius M., Slawska J., Jacobs L., Ahangarian Abhari B., Altmann B., Kurutz J., Rathakrishnan A., Fernández-Sáiz V., Brunner A., et al.  USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive B-cell lymphoma. EMBO Mol. Med. 2016;8:851–862. doi: 10.15252/emmm.201506047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15252/emmm.201506047</ArticleId>
            <ArticleId IdType="pmc">PMC4967940</ArticleId>
            <ArticleId IdType="pubmed">27317434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kapuria V., Peterson L.F., Fang D., Bornmann W.G., Talpaz M., Donato N.J. Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Res. 2010;70:9265–9276. doi: 10.1158/0008-5472.CAN-10-1530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-10-1530</ArticleId>
            <ArticleId IdType="pubmed">21045142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ishida C.T., Bianchetti E., Shu C., Halatsch M.E., Westhoff M.A., Karpel-Massler G., Siegelin M.D. BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma. Oncotarget. 2017;8:29558–29573. doi: 10.18632/oncotarget.16365.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.16365</ArticleId>
            <ArticleId IdType="pmc">PMC5444687</ArticleId>
            <ArticleId IdType="pubmed">28418907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singleton D.C., Harris A.L. Targeting the ATF4 pathway in cancer therapy. Expert Opin. Ther. Targets. 2012;16:1189–1202. doi: 10.1517/14728222.2012.728207.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1517/14728222.2012.728207</ArticleId>
            <ArticleId IdType="pubmed">23009153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan J., Zhong N., Liu G., Chen K., Liu X., Su L., Singhal S. Usp9x- and Noxa-mediated Mcl-1 downregulation contributes to pemetrexed-induced apoptosis in human non-small-cell lung cancer cells. Cell Death Dis. 2014;5:e1316. doi: 10.1038/cddis.2014.281.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cddis.2014.281</ArticleId>
            <ArticleId IdType="pmc">PMC4123075</ArticleId>
            <ArticleId IdType="pubmed">24991768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Di Meo S., Reed T.T., Venditti P., Victor V.M. Role of ROS and RNS sources in physiological and pathological conditions. Oxid. Med. Cell Longev. 2016;2016:1245049. doi: 10.1155/2016/1245049.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2016/1245049</ArticleId>
            <ArticleId IdType="pmc">PMC4960346</ArticleId>
            <ArticleId IdType="pubmed">27478531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eletto D., Chevet E., Argon Y., Appenzeller-Herzog C. Redox controls UPR to control redox. J. Cell Sci. 2014;127:3649–3658. doi: 10.1242/jcs.153643.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/jcs.153643</ArticleId>
            <ArticleId IdType="pubmed">25107370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fulda S., Gorman A.M., Hori O., Samali A. Cellular stress responses: Cell survival and cell death. Int. J. Cell Biol. 2010;2010:214074. doi: 10.1155/2010/214074.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2010/214074</ArticleId>
            <ArticleId IdType="pmc">PMC2825543</ArticleId>
            <ArticleId IdType="pubmed">20182529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Düvel K., Yecies J.L., Menon S., Raman P., Lipovsky A.I., Souza A.L., Triantafellow E., Ma Q., Gorski R., Cleaver S., et al.  Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell. 2010;39:171–183. doi: 10.1016/j.molcel.2010.06.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2010.06.022</ArticleId>
            <ArticleId IdType="pmc">PMC2946786</ArticleId>
            <ArticleId IdType="pubmed">20670887</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
